Hiroyasu Kashima1, Ren-Chin Wu2, Yihong Wang3, Abdulrahman K Sinno4, Tsutomu Miyamoto5, Tanri Shiozawa5, Tian-Li Wang6, Amanda N Fader4, Ie-Ming Shih7. 1. Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Japan. 2. Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 3. Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Japan; Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China. 4. Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD, United States. 5. Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Japan. 6. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. 7. Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD, United States; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. Electronic address: ishih@jhmi.edu.
Abstract
OBJECTIVES: Molecular markers associated with tumor progression in uterine carcinoma are poorly defined. In this study, we determine whether upregulation of LAMC1, a gene encoding extracellular matrix protein, laminin γ1, is associated with various uterine carcinoma subtypes and stages of tumor progression. METHODS: An analysis of the immunostaining patterns of laminin γ1 in normal endometrium, atypical hyperplasia, and a total of 150 uterine carcinomas, including low-grade and high-grade endometrioid carcinomas, uterine serous and clear cell carcinoma, was performed. Clinicopathological correlation was performed to determine biological significance. The Cancer Genome Atlas (TCGA) data set was used to validate our results. RESULTS: As compared to normal proliferative and secretory endometrium, for which laminin γ1 immunoreactivity was almost undetectable, increasing laminin C1 staining intensity was observed in epithelial cells from atypical hyperplasia to low-grade endometrioid to high-grade endometrioid carcinoma, respectively. Laminin γ1 expression was significantly associated with FIGO stage, myometrial invasion, cervical/adnexal involvement, angiolymphatic invasion and lymph node metastasis. Similarly, analysis of the endometrial carcinoma data set from TCGA revealed that LAMC1 transcript levels were higher in high-grade than those in low-grade endometrioid carcinoma. Silencing LAMC1 expression by siRNAs in a high-grade endometrioid carcinoma cell line did not affect its proliferative activity but significantly suppressed cell motility and invasion in vitro. CONCLUSIONS: These data suggest that laminin γ1 may contribute to the development and progression of uterine carcinoma, likely through enhancing tumor cell motility and invasion. Laminin γ1 warrants further investigation regarding its role as a biomarker and therapeutic target in uterine carcinoma.
OBJECTIVES: Molecular markers associated with tumor progression in uterine carcinoma are poorly defined. In this study, we determine whether upregulation of LAMC1, a gene encoding extracellular matrix protein, laminin γ1, is associated with various uterine carcinoma subtypes and stages of tumor progression. METHODS: An analysis of the immunostaining patterns of laminin γ1 in normal endometrium, atypical hyperplasia, and a total of 150 uterine carcinomas, including low-grade and high-grade endometrioid carcinomas, uterine serous and clear cell carcinoma, was performed. Clinicopathological correlation was performed to determine biological significance. The Cancer Genome Atlas (TCGA) data set was used to validate our results. RESULTS: As compared to normal proliferative and secretory endometrium, for which laminin γ1 immunoreactivity was almost undetectable, increasing laminin C1 staining intensity was observed in epithelial cells from atypical hyperplasia to low-grade endometrioid to high-grade endometrioid carcinoma, respectively. Laminin γ1 expression was significantly associated with FIGO stage, myometrial invasion, cervical/adnexal involvement, angiolymphatic invasion and lymph node metastasis. Similarly, analysis of the endometrial carcinoma data set from TCGA revealed that LAMC1 transcript levels were higher in high-grade than those in low-grade endometrioid carcinoma. Silencing LAMC1 expression by siRNAs in a high-grade endometrioid carcinoma cell line did not affect its proliferative activity but significantly suppressed cell motility and invasion in vitro. CONCLUSIONS: These data suggest that laminin γ1 may contribute to the development and progression of uterine carcinoma, likely through enhancing tumor cell motility and invasion. Laminin γ1 warrants further investigation regarding its role as a biomarker and therapeutic target in uterine carcinoma.
Authors: Guangming Han; Robert A Soslow; Stephanie Wethington; Douglas A Levine; Faina Bogomolniy; Philip B Clement; Martin Köbel; Blake Gilks; Deborah DeLair Journal: Int J Gynecol Pathol Date: 2015-07 Impact factor: 2.762
Authors: Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin Journal: Proc Natl Acad Sci U S A Date: 2013-01-28 Impact factor: 11.205
Authors: Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz Journal: Sci Transl Med Date: 2013-01-09 Impact factor: 17.956
Authors: Konrad Futyma; Paweł Miotła; Krystyna Różyńska; Małgorzata Zdunek; Andrzej Semczuk; Tomasz Rechberger; Jacek Wojcierowski Journal: Oncol Rep Date: 2014-09-17 Impact factor: 3.906
Authors: Kwang Man Park; Hong Jae Lee; Ki-Tae Koo; Heithem Ben Amara; Richard Leesungbok; Kwantae Noh; Sang Cheon Lee; Suk Won Lee Journal: Tissue Eng Regen Med Date: 2020-01-22 Impact factor: 4.169
Authors: Vladimir V Galatenko; Diana V Maltseva; Alexey V Galatenko; Sergey Rodin; Alexander G Tonevitsky Journal: BMC Med Genomics Date: 2018-02-13 Impact factor: 3.063
Authors: Amit Kulkarni; Tiago Ferreira; Clemens Bretscher; Annabel Grewenig; Nazim El-Andaloussi; Serena Bonifati; Tiina Marttila; Valérie Palissot; Jubayer A Hossain; Francisco Azuaje; Hrvoje Miletic; Lars A R Ystaas; Anna Golebiewska; Simone P Niclou; Ralf Roeth; Beate Niesler; Amélie Weiss; Laurent Brino; Antonio Marchini Journal: Nat Commun Date: 2021-06-22 Impact factor: 14.919
Authors: Ricky Cordova; Kelli Kiekens; Susan Burrell; William Drake; Zaynah Kmeid; Photini Rice; Andrew Rocha; Sebastian Diaz; Shigehiro Yamada; Michael Yozwiak; Omar L Nelson; Gustavo C Rodriguez; John Heusinkveld; Ie-Ming Shih; David S Alberts; Jennifer K Barton Journal: J Biomed Opt Date: 2021-07 Impact factor: 3.170